Publications by authors named "C Ganzel"

Claim this Profile
T
Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.
Ofir Wolach, Itai Levi, Boaz Nachmias, Sigal Tavor, Irina Amitai, Chezi Ganzel

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
Avraham Frisch, Chezi Ganzel, Yishai Ofran, Baher Krayem, Arnon Haran

Eur J Haematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem

Br J Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Eitan Kugler, Inbar Cohen, Irina Amitai, Ron Ram, Avraham Frisch, Chezi Ganzel

Br J Haematol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
C Ganzel, Y Wang, K Roopcharan, Z Sun, J M Rowe

Bone Marrow Transplant· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis